CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.88 -0.03 (-3.19%)
As of: Oct 22, 2026 · 12:25 PM EDT

CytoMed Therapeutics (GDTC) Other Non-Current Liabilities (2023 - 2026)

Updated

CytoMed Therapeutics (GDTC) posted Other Non-Current Liabilities of $20,698 for Q2 2026, down 76.6% from $88,268 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics' Other Non-Current Liabilities came in at $19,184, up 114.5% from FY2024.

  • In prior years, CytoMed Therapeutics' Other Non-Current Liabilities was $8,942 in FY2024 (-91.8%) and $109,199 in FY2023.
  • Quarterly Other Non-Current Liabilities has run from a low of $8,980 in Q4 2024 to a high of $108,595 in Q4 2023 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,172.40 Bn 1,140.99 Bn 19.71 Bn
2 Johnson & Johnson 642.90 Bn 561.42 Bn 17.26 Bn
3 AbbVie 502.02 Bn 475.14 Bn 12.70 Bn
4 Merck 375.88 Bn 330.26 Bn 12.21 Bn
5 Novartis Ag 302.81 Bn 266.80 Bn 11.24 Bn
6 Astrazeneca 268.58 Bn 242.27 Bn 12.86 Bn
7 Amgen 242.38 Bn 197.78 Bn 7.24 Bn
8 Gilead Sciences 193.63 Bn 167.83 Bn 6.22 Bn
9 Pfizer 172.59 Bn 119.24 Bn 10.94 Bn
10 CytoMed Therapeutics 10.29 Mn 1.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 20,698.00
Dec 31, 2025 19,521.77
Jun 30, 2025 88,268.00
Dec 31, 2024 8,787.81
Dec 31, 2023 111,087.28
API Access

CytoMed Therapeutics Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=GDTC&period=max&api_key=YOUR_API_KEY